ProSci Company News

Find out the latest information about ProSci below!


Sort by:

August 28, 2017
Press Release
Flow Cytometry
Monoclonal
Screening
Custom Service
ProSci Inc. Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
Flow cytometry screening for custom monoclonal antibody development

San Diego, CA: ProSci Inc., a San Diego-based privately held biotechnology firm, has announced that it will add flow cytometry to the list of current screening services offered for monoclonal antibody development services: mouse hybridoma development, rabbit monoclonal antibody, and single domain antibody. This service will be available for purchase beginning in August 2017.

“Our priority at ProSci Incorporated is to provide the highest quality monoclonal, polyclonal, and single domain antibody services in the industry,” says, David Eling, Ph.D. Director of Business Development, “We saw a need for scientists and researchers developing flow antibodies in our industry, and decided to incorporate flow cytometry into our current screening service offering for monoclonal antibody development.”

The flow cytometry screening service will include screening up to two cell line for positively expressed protein targets of interest throughout each phase of development. Additional cell line screening can also be performed at added cost.

The addition of flow cytometry to ProSci’s offerings will increase the value of the services to scientists, researchers, and other technologists. Since many antibody manufacturers only have Western blot and ELISA screening capabilities, relying on outsourcing to test their antibodies in flow independently.

Learn more about flow cytometry screening here
July 31, 2016
Press Release
Single Domain
Immune Checkpoint
Cancer
Product
ProSci Incorporated Releases New Anti-PD-L1 Single Domain Antibodies (sdAbs)
Single domain antibodies targeting the immune checkpoint target PD-L1

San Diego, CA: ProSci Incorporated, a leading provider of antibody related services and products, is proud to announce the release of multiple single domain antibodies against the human programmed death ligand 1 (PD-L1). These single domain antibodies (sdAbs) are now available for purchase at www.prosci-inc.com and contain both Myc and His tags.

SdAbs are the smallest fully functional antibodies on the market. sdAbs are highly stable and being only 15 kDa in size, enable binding to epitopes that are inaccessible to traditional antibodies. Developed recombinantly using phage display technology, these antibodies offer high affinity and specificity providing reproducible PD-L1 antigen recognition.

PD-L1 can be found on the surface of tumor cells and plays a pivotal role in tumor cells evading detection and the removal from a critical checkpoint inhibitor. High quality detection of PD-L1 is crucial for researchers studying cancer and sdAbs provide a reliable and reproducible resource. ProSci’s PD-L1 sdAbs are positive by: enzyme-linked immunosorbent assay (ELISA), Flow Cytometry, and immunocytochemistry (ICC).

“The unique characteristics of single domain antibodies empower them to be valuable tools for diagnostics, therapeutics, imaging and structural biology. ProSci’s RnD team continues to expand its portfolio of sdAbs against immune checkpoint targets and is proud of our latest release of sdAbs against hPD-L1. It is our hope that these sdAbs will be useful for researchers in advancing science. ProSci offers a full range of services and is open to collaborations and partnerships, including the development of new sdAbs.” David Eling, Ph.D. Director of Business Development.

To place an order for ProSci’s PD-L1 single domain antibodies (Cat. No. SD8585 and SD8623), visit www.prosci-inc.com.
March 20, 2016
Press Release
Rabbit Monoclonal
Plasma Cell
Technology
Custom Service
ProSci Incorporated Now Offers Rabbit Monoclonal Services
Leading Developer of Custom Antibodies Provides Rabbit Monoclonal Services

Poway, CA: On March 20, 2016, ProSci Incorporated launched its new Custom Rabbit Monoclonal Antibody service. The rabbit monoclonal services is the latest addition to ProSci’s Custom Antibody development services and stands apart with Isolated Plasma Cell Technology. This technology isolates mature plasma cells before cloning to generate more diverse antibodies with greater affinity and specificity while traditional monoclonal antibody generating technologies hybridoma, phage display, or B-cell cloning use the undifferentiated B-cells. The company is one of the first to utilize this technology commercially.

ProSci Inc develops custom rabbit monoclonal antibodies for research in designing vaccines, diagnostics, therapeutics and related products. Customers provide ProSci with their antigen or target to design an antigen against and in three to four months, an ELISA report, 200ug of purified antibody for up to five clones, as well as the sequences is delivered with the option of additional production.

ProSci recognizes that rabbit monoclonal antibodies are highly valuable because the rabbit immune system is particularly unique and generates a plethora of diverse antibodies and binding affinity optimization not found in other animals commonly used in research. The process of rabbit immunization generates a wide selection of B-lymphocytes as well as splenocytes and in comparison to mouse monoclonal antibodies, rabbit monoclonal antibodies can typically achieve binding affinities that are 10 to 100 times stronger.

ProSci Inc has over 17 years of experience and specializes in custom polyclonal, monoclonal, and single domain antibody development and production. ProSci routinely takes on some of the most challenging targets including small molecule compounds, point mutations, post-translational modifications, splice variants and species-specific orthologs. The firm stands apart from competitors by ensuring every single client is provided with high quality technical assistance, competitive pricing, and highly customizable projects. ProSci Inc’s antibodies have been widely published, appearing in many prestigious journals worldwide. Regardless of the complexity of the research project, the ProSci Inc team is ready and skilled to tailor its suite of services to the specific needs of each client’s project. The firm’s state-of-the-art facilities are equipped with the technology to handle immunogens in a wide array of forms including basic cells, pathological tissue samples or synthetic peptides. ProSci Inc’s expertise and advanced technology positions the firm well to meet clients at every stage in the research process and deliver rabbit monoclonal antibody services with rapidity and reliability.